Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib in BRAF V600E-mutant non-small cell lung cancer
NL-OMON59265Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of encorafenib and binimetinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Pfizer. Primary endpoints: Objective response rate in treatment-naive cohort and Objective response rate in previously treated cohort. Started Nov 2019; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59265.